查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1776781

2032 年個人化醫療市場預測：按產品、技術、應用、最終用戶和地區進行的全球分析

Personalized Medicine Market Forecasts to 2032 - Global Analysis By Product, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球個人化醫療市場預計在 2025 年達到 6,428 億美元，到 2032 年將達到 1,2,686 億美元，預測期內的複合年成長率為 10.2%。

個人化醫療，又稱精準醫療，是一種根據個人遺傳、環境和生活方式因素量身定做治療和預防策略的醫療方法。它利用基因組學、診斷學和數據分析領域的進步來預測疾病風險、選擇最佳治療方法並改善患者預後。與傳統的「一刀切」模式不同，個人化醫療可以提高藥物療效、減少副作用並支持早期發現。它透過在腫瘤學、心臟病學和罕見遺傳疾病等領域實現標靶治療，正在改變醫療保健領域。

增加對標靶治療和研發的投資

由於針對個別患者特徵的標靶治療投入不斷增加，個人化醫療市場正在經歷顯著成長。基因組學研究的進展使得針對各種疾病的精準治療成為可能。公共和私營部門的資金投入不斷增加，加速了個人化醫療技術的創新。製藥公司和研究機構之間的合作正在催生突破性的個人化治療方案。此外，政府支持精準醫療研究的措施也進一步推動了市場的擴張。

個人化醫療保健的保險覆蓋範圍有限

個人化醫療診斷和治療的高昂成本，是其廣泛應用的一大障礙。許多保險公司限制對高級基因組檢測和標靶治療的承保，增加了患者的自付費用。個人化醫療服務缺乏標準化的報銷政策，為病患和醫療服務提供者都帶來了經濟挑戰。這些經濟負擔可能會阻礙患者接受個人化醫療，並限制市場成長。努力擴大保險覆蓋範圍並簡化報銷流程，對於克服這項限制至關重要。

藥物基因組學和伴隨診斷的發展

藥物基因體學的興起創造了新的機會，它能夠根據個體基因圖譜實現個人化藥物治療。伴隨診斷因其能夠更準確地預測治療效果和安全性而日益普及。預防性醫療保健的日益普及，推動了對藥物基因體學檢測的需求，從而最佳化了藥物處方。在新興市場，醫療基礎設施的改善正在推動伴隨診斷的應用激增。此外，人工智慧和數據分析的進步也提高了這些診斷工具的準確性和可近性。

醫療保健IT基礎設施缺乏互通性

缺乏標準化的醫療IT系統阻礙了個人化醫療數據跨平台的無縫整合。不一致的數據格式和通訊協定使醫療服務提供者之間共用關鍵患者資訊變得複雜。缺乏互通性導致診斷和治療計畫效率低下，影響患者治療效果。升級傳統IT系統以支援個人化醫療應用的高成本構成了重大挑戰。如果沒有統一的標準，個人化醫療解決方案的擴充性將仍然有限，從而威脅市場成長。

COVID-19的影響：

新冠疫情擾亂了個人化醫療市場，導致非必要的診斷程序和臨床試驗被推遲。然而，疫情也加速了遠端醫療的普及，使遠距會診能夠制定個人化治療方案。這場危機凸顯了快速基因序列測定在標靶治療開發中的重要性，並促進了該領域的研究。供應鏈中斷暫時影響了診斷工具和試劑的供應。疫情後的復甦預計將進一步凸顯精準診斷在感染疾病和慢性病管理中的作用。

個人化醫療診斷領域預計將成為預測期內最大的領域

由於對精準早期疾病檢測的需求日益成長，個人化醫療診斷領域預計將在預測期內佔據最大的市場佔有率。基因組定序技術的進步使得更精準的診斷工具能夠用於個人化治療。醫療保健提供者對個人化診斷益處的認知不斷提高，推動了其應用。研發投入正在催生更精準、更具創新性的診斷平台。此外，政府的支持性政策和對精準醫療計畫的資助也推動了該領域的成長。

預計預測期內腫瘤學領域將以最高的複合年成長率成長。

預計腫瘤學領域將在預測期內實現最高成長率，這得益於全球癌症發生率的上升以及對標靶治療的需求。基因組分析的創新使得針對每位患者量身定做的精準腫瘤治療成為可能。癌症研究資金的增加促進了個人化癌症診斷和治療方法的進步。癌症研究中心和製藥公司之間的合作正在推動市場成長。此外，人們對早期癌症檢測意識的不斷提高也推動了對個人化腫瘤學解決方案的需求。

佔比最大的地區：

預計亞太地區將在預測期內佔據最大的市場佔有率，這得益於中國和印度等國家醫療基礎設施的快速改善。該地區慢性病的盛行率不斷上升，推動了對個人化醫療解決方案的需求。政府旨在推廣精準醫療和解決醫療差距的措施正在推動市場成長。醫療支出的增加和患者對個人化治療意識的增強是關鍵因素。此外，與全球製藥公司的合作也正在增強人們獲得先進個人化醫療技術的管道。

複合年成長率最高的地區：

預計北美將在預測期內實現最高的複合年成長率，這得益於其完善的醫療基礎設施和對精準醫療研究的大量投資。大型製藥和生物技術公司的湧現正在推動個人化醫療解決方案的創新。醫療保健提供者和患者對個人化治療益處的認知不斷提高，也是主要的成長動力。

提供免費客製化：

此報告的訂閱者可以使用以下免費自訂選項之一：

  • 公司簡介
    • 對最多三家其他市場公司進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 技術分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

第5章全球個人化醫療市場（按產品）

  • 個性化醫療診斷
    • 基因檢測
    • 直接面對消費者 (DTC) 的診斷
    • 深奧化驗服務
    • 困難的實驗室篩檢
  • 個人化醫療
    • 製藥
    • 基因組醫學
    • 醫療設備
  • 個人化醫療
    • 遠端醫療
    • 醫療資訊技術
  • 個人化營養與健康
    • 零售營養
    • 補充和替代醫學

6. 全球個人化醫療市場（按技術）

  • 巨量資料分析
  • 人工智慧
  • 生物資訊學
  • 基因序列分析
  • 藥物研發
  • 其他技術

7. 全球個人化醫療市場（按應用）

  • 腫瘤學
  • 中樞神經系統
  • 免疫學
  • 呼吸系統
  • 肝
  • 風濕病
  • 其他用途

第8章全球個人化醫療市場（依最終用戶）

  • 醫院
  • 診斷中心
  • 研究和學術機構
  • 其他最終用戶

9. 全球個人化醫療市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第10章：主要發展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司概況

  • GE Healthcare
  • Illumina, Inc.
  • ASURAGEN, INC.
  • Abbott
  • Dako A/S
  • Exact Sciences Corporation
  • Danaher Corporation（Cepheid, Inc.）
  • Decode Genetics, Inc.
  • QIAGEN
  • Exagen Inc.
  • Precision Biologics
  • Celera Diagnostics LLC.
  • Biogen
  • Genelex
  • International Business Machines Corporation（IBM）
  • Genentech, Inc.
  • 23andMe, Inc.
Product Code: SMRC30112

According to Stratistics MRC, the Global Personalized Medicine Market is accounted for $642.8 billion in 2025 and is expected to reach $1268.6 billion by 2032 growing at a CAGR of 10.2% during the forecast period. Personalized Medicine, also known as precision medicine, is a medical approach that tailors treatment and prevention strategies to individual genetic, environmental, and lifestyle factors. It leverages advances in genomics, diagnostics, and data analytics to predict disease risks, select optimal therapies, and improve patient outcomes. Unlike traditional one-size-fits-all models, personalized medicine enhances drug efficacy, reduces side effects, and supports early detection. It is transforming healthcare by enabling targeted treatments in fields like oncology, cardiology, and rare genetic disorders.

Market Dynamics:

Driver:

Growing investment in targeted therapies and R&D

The personalized medicine market is experiencing significant growth due to increased investments in targeted therapies tailored to individual patient profiles. Advancements in genomic research are enabling the development of precision treatments for various diseases. Rising funding from both public and private sectors is accelerating innovation in personalized medicine technologies. Collaborative efforts between pharmaceutical companies and research institutions are fostering breakthroughs in personalized treatment options. Additionally, government initiatives supporting precision medicine research are further propelling market expansion.

Restraint:

Limited insurance coverage for personalized healthcare

The high cost of personalized medicine diagnostics and treatments poses a significant barrier to widespread adoption. Many insurance providers offer limited coverage for advanced genomic testing and targeted therapies, increasing out-of-pocket expenses for patients. The lack of standardized reimbursement policies for personalized healthcare services creates financial challenges for both patients and providers. This financial burden can discourage patients from seeking personalized care, limiting market growth. Efforts to expand insurance coverage and streamline reimbursement processes are critical to overcoming this restraint.

Opportunity:

Growth in pharmacogenomics and companion diagnostics

The rise of pharmacogenomics is creating new opportunities by enabling tailored drug therapies based on individual genetic profiles. Companion diagnostics are gaining traction, allowing for more accurate prediction of treatment efficacy and safety. The growing emphasis on preventive healthcare is boosting demand for pharmacogenomic testing to optimize drug prescriptions. Emerging markets are witnessing a surge in adoption of companion diagnostics due to improving healthcare infrastructure. Additionally, advancements in AI and data analytics are enhancing the precision and accessibility of these diagnostic tools.

Threat:

Lack of interoperability in healthcare IT infrastructure

The absence of standardized healthcare IT systems hinders seamless integration of personalized medicine data across platforms. Inconsistent data formats and protocols complicate the sharing of critical patient information among healthcare providers. This lack of interoperability can lead to inefficiencies in diagnosis and treatment planning, impacting patient outcomes. The high cost of upgrading legacy IT systems to support personalized medicine applications poses a significant challenge. Without unified standards, the scalability of personalized medicine solutions remains limited, threatening market growth.

Covid-19 Impact:

The COVID-19 pandemic disrupted the personalized medicine market by delaying non-essential diagnostic procedures and clinical trials. However, it accelerated the adoption of telemedicine, enabling remote consultations for personalized treatment plans. The crisis highlighted the importance of rapid genetic sequencing for developing targeted therapies, boosting research in this area. Supply chain disruptions temporarily affected the availability of diagnostic tools and reagents. Post-pandemic recovery is expected to further emphasize the role of precision diagnostics in managing infectious and chronic diseases.

The personalized medicine diagnostics segment is expected to be the largest during the forecast period

The personalized medicine diagnostics segment is expected to account for the largest market share during the forecast period, owing to the increasing demand for accurate and early disease detection. Advancements in genomic sequencing technologies are enabling more precise diagnostic tools for tailored treatments. Rising awareness among healthcare providers about the benefits of personalized diagnostics is driving adoption. Investments in research and development are leading to innovative diagnostic platforms with higher accuracy. Additionally, supportive government policies and funding for precision medicine initiatives are bolstering this segment's growth.

The oncology segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the oncology segment is predicted to witness the highest growth rate, impelled by the rising incidence of cancer globally and the need for targeted therapies. Innovations in genomic profiling are enabling the development of precision oncology treatments tailored to individual patients. Increased funding for cancer research is driving advancements in personalized cancer diagnostics and therapies. Collaborative efforts between oncology research centers and pharmaceutical companies are accelerating market growth. Furthermore, heightened awareness of early cancer detection is boosting demand for personalized oncology solutions.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, driven by rapid improvements in healthcare infrastructure across countries like China and India. The increasing prevalence of chronic diseases in the region is boosting demand for personalized medicine solutions. Government initiatives aimed at promoting precision medicine and reducing healthcare disparities are fueling market growth. Rising healthcare expenditure and growing awareness of personalized treatments among patients are key contributors. Additionally, collaborations with global pharmaceutical companies are enhancing access to advanced personalized medicine technologies.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR attributed to, its well-established healthcare infrastructure and significant investments in precision medicine research. The presence of leading pharmaceutical and biotechnology companies drives innovation in personalized medicine solutions. Increasing awareness among healthcare providers and patients about the benefits of personalized treatments is a key growth driver.

Key players in the market

Some of the key players in Personalized Medicine Market include GE Healthcare, Illumina, Inc., ASURAGEN, INC., Abbott, Dako A/S, Exact Sciences Corporation, Danaher Corporation (Cepheid, Inc.), Decode Genetics, Inc., QIAGEN, Exagen Inc., Precision Biologics, Celera Diagnostics LLC., Biogen, Genelex, International Business Machines Corporation (IBM), Genentech, Inc., and 23andMe, Inc.

Key Developments:

In May 2025, Illumina and Ovation.io introduced a groundbreaking GLP-1 multi-omic dataset encompassing 25,000 patient profiles. This initiative aims to accelerate precision medicine by enhancing drug response prediction, enabling researchers to refine targeted therapies using integrated genomic, proteomic, and metabolomic insights.

In May 2025, Illumina expanded its clinical oncology offerings by launching the Pillar oncoReveal(R)CDx panel. This companion diagnostic tool supports personalized cancer therapy, offering broader access to genomic profiling and enabling clinicians to align treatments more effectively with patients' tumor-specific genetic mutations.

Products Covered:

  • Personalized Medicine Diagnostics
  • Personalized Medicine Therapeutics
  • Personalized Medical Care
  • Personalized Nutrition and Wellness

Technologies Covered:

  • Big Data Analytics
  • Artificial Intelligence
  • Bioinformatics
  • Gene Sequencing
  • Drug Discovery
  • Other Technologies

Applications Covered:

  • Oncology
  • CNS
  • Immunology
  • Respiratory
  • Liver
  • Rheumatology
  • Other Applications

End Users Covered:

  • Hospitals
  • Diagnostic Centers
  • Research & Academic Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Personalized Medicine Market, By Product

  • 5.1 Introduction
  • 5.2 Personalized Medicine Diagnostics
    • 5.2.1 Genetic Testing
    • 5.2.2 Direct-To-Consumer (DTC) Diagnostics
    • 5.2.3 Esoteric Lab Services
    • 5.2.4 Esoteric Lab Tests
  • 5.3 Personalized Medicine Therapeutics
    • 5.3.1 Pharmaceutical
    • 5.3.2 Genomic Medicine
    • 5.3.3 Medical Devices
  • 5.4 Personalized Medical Care
    • 5.4.1 Telemedicine
    • 5.4.2 Health Information Technology
  • 5.5 Personalized Nutrition & Wellness
    • 5.5.1 Retail Nutrition
    • 5.5.2 Complementary & Alternative Medicine

6 Global Personalized Medicine Market, By Technology

  • 6.1 Introduction
  • 6.2 Big Data Analytics
  • 6.3 Artificial Intelligence
  • 6.4 Bioinformatics
  • 6.5 Gene Sequencing
  • 6.6 Drug Discovery
  • 6.7 Other Technologies

7 Global Personalized Medicine Market, By Application

  • 7.1 Introduction
  • 7.2 Oncology
  • 7.3 CNS
  • 7.4 Immunology
  • 7.5 Respiratory
  • 7.6 Liver
  • 7.7 Rheumatology
  • 7.8 Other Applications

8 Global Personalized Medicine Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals
  • 8.3 Diagnostic Centers
  • 8.4 Research & Academic Institutes
  • 8.5 Other End Users

9 Global Personalized Medicine Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 GE Healthcare
  • 11.2 Illumina, Inc.
  • 11.3 ASURAGEN, INC.
  • 11.4 Abbott
  • 11.5 Dako A/S
  • 11.6 Exact Sciences Corporation
  • 11.7 Danaher Corporation (Cepheid, Inc.)
  • 11.8 Decode Genetics, Inc.
  • 11.9 QIAGEN
  • 11.10 Exagen Inc.
  • 11.11 Precision Biologics
  • 11.12 Celera Diagnostics LLC.
  • 11.13 Biogen
  • 11.14 Genelex
  • 11.15 International Business Machines Corporation (IBM)
  • 11.16 Genentech, Inc.
  • 11.17 23andMe, Inc.

List of Tables

  • Table 1 Global Personalized Medicine Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Personalized Medicine Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Personalized Medicine Market Outlook, By Personalized Medicine Diagnostics (2024-2032) ($MN)
  • Table 4 Global Personalized Medicine Market Outlook, By Genetic Testing (2024-2032) ($MN)
  • Table 5 Global Personalized Medicine Market Outlook, By Direct-To-Consumer (DTC) Diagnostics (2024-2032) ($MN)
  • Table 6 Global Personalized Medicine Market Outlook, By Esoteric Lab Services (2024-2032) ($MN)
  • Table 7 Global Personalized Medicine Market Outlook, By Esoteric Lab Tests (2024-2032) ($MN)
  • Table 8 Global Personalized Medicine Market Outlook, By Personalized Medicine Therapeutics (2024-2032) ($MN)
  • Table 9 Global Personalized Medicine Market Outlook, By Pharmaceutical (2024-2032) ($MN)
  • Table 10 Global Personalized Medicine Market Outlook, By Genomic Medicine (2024-2032) ($MN)
  • Table 11 Global Personalized Medicine Market Outlook, By Medical Devices (2024-2032) ($MN)
  • Table 12 Global Personalized Medicine Market Outlook, By Personalized Medical Care (2024-2032) ($MN)
  • Table 13 Global Personalized Medicine Market Outlook, By Telemedicine (2024-2032) ($MN)
  • Table 14 Global Personalized Medicine Market Outlook, By Health Information Technology (2024-2032) ($MN)
  • Table 15 Global Personalized Medicine Market Outlook, By Personalized Nutrition & Wellness (2024-2032) ($MN)
  • Table 16 Global Personalized Medicine Market Outlook, By Retail Nutrition (2024-2032) ($MN)
  • Table 17 Global Personalized Medicine Market Outlook, By Complementary & Alternative Medicine (2024-2032) ($MN)
  • Table 18 Global Personalized Medicine Market Outlook, By Technology (2024-2032) ($MN)
  • Table 19 Global Personalized Medicine Market Outlook, By Big Data Analytics (2024-2032) ($MN)
  • Table 20 Global Personalized Medicine Market Outlook, By Artificial Intelligence (2024-2032) ($MN)
  • Table 21 Global Personalized Medicine Market Outlook, By Bioinformatics (2024-2032) ($MN)
  • Table 22 Global Personalized Medicine Market Outlook, By Gene Sequencing (2024-2032) ($MN)
  • Table 23 Global Personalized Medicine Market Outlook, By Drug Discovery (2024-2032) ($MN)
  • Table 24 Global Personalized Medicine Market Outlook, By Other Technologies (2024-2032) ($MN)
  • Table 25 Global Personalized Medicine Market Outlook, By Application (2024-2032) ($MN)
  • Table 26 Global Personalized Medicine Market Outlook, By Oncology (2024-2032) ($MN)
  • Table 27 Global Personalized Medicine Market Outlook, By CNS (2024-2032) ($MN)
  • Table 28 Global Personalized Medicine Market Outlook, By Immunology (2024-2032) ($MN)
  • Table 29 Global Personalized Medicine Market Outlook, By Respiratory (2024-2032) ($MN)
  • Table 30 Global Personalized Medicine Market Outlook, By Liver (2024-2032) ($MN)
  • Table 31 Global Personalized Medicine Market Outlook, By Rheumatology (2024-2032) ($MN)
  • Table 32 Global Personalized Medicine Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 33 Global Personalized Medicine Market Outlook, By End User (2024-2032) ($MN)
  • Table 34 Global Personalized Medicine Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 35 Global Personalized Medicine Market Outlook, By Diagnostic Centers (2024-2032) ($MN)
  • Table 36 Global Personalized Medicine Market Outlook, By Research & Academic Institutes (2024-2032) ($MN)
  • Table 37 Global Personalized Medicine Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.